Previous multivariate analysis reveals that AML patients with a single TP53 deletion have a worse treatment outcome than patients with NK, and it was suggested that TP53 deletion should be classified into the high-risk category for developing risk-adapted treatment strategies in AML [320]. This evidence concerns the gene TP53 and acute myeloid leukemia.